Apoptosis modulators as cancer therapeutics

Current Opinion in Investigational Drugs

Volumn 2, Issue 5, 2001, Pages 684-692

  Penn, L Z ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Apoptosis; Cancer; Drug development; Programmed cell death; Therapeutics; Tumor

Indexed keywords

17 AAG; 17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; APOPTOSIS INDUCING FACTOR; CERIVASTATIN; CYTOSTATIC AGENT; DACARBAZINE; DOCETAXEL; GELDANAMYCIN; GERANYLTRANSFERASE; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; MEVALONIC ACID; MEVINOLIN; OBLIMERSEN; PACLITAXEL; PRODRUG; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN P53; PYROXAMIDE; RADICICOL; STATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CELL; CANCER INHIBITION; CARCINOGENESIS; CELL SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; GENE THERAPY; GENETIC DISORDER; HUMAN; LIVER TOXICITY; MONOTHERAPY; NONHUMAN; ONCOGENE C MYC; PROTO ONCOGENE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 0034990111     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Apoptosis: A basic biological phenomenon with wide-ranging implications in tissue kinetics
2. Cell death: The significance of apoptosis
3. Genetic control of programmed cell death in the nematode C elegans
4. Caenorhabditis elegans gene ced-9 protects cells from programmed cell death
5. The C elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme
6. C elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2
7. Apoptosis in cancer: Cause and cure
8. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
9. Biochemical pathways of caspase activation during apoptosis
10. Apoptosis control by death and decoy receptors
11. Bcl-2 family proteins
12. BCL-2 family members and the mitochondria in apoptosis
13. Apoptosis and therapy
14. A matter of life and cell death
15. Cell suicide for beginners
16. The hallmarks of cancer
17. Induction of apoptosis by cancer chemotherapy
18. Inhibition of apoptosis during development of colorectal cancer
19. Quantitative monitoring of gene expression patterns with a complementary DNA microarray
20. Tissue microarrays: What will they bring to molecular and anatomic pathology?
21. The impact of genomics on therapeutic drug development
22. Genome changes and gene expression in human solid tumors
23. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
24. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray
25. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
26. DNA microarrays in drug discovery and development
27. Expression profiling using cDNA microarrays
28. Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
29. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice
30. Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
31. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
32. Chemosensitisation of malignant melanoma by BCL2 antisense therapy
33. Phase 1 trial of genasense (G3139, Genta, Inc), a bcl-2 antisense, in refractory or relapsed acute leukemia
34. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily
35. Molecular cloning and characterisation of a novel putative protein-serine kinase related to the cAMP-dependent and protein kinase C families
36. A retroviral oncogene, akt, encoding a serine-threonine kinase containing an SH2-like region
37. Structure, expression and chromosomal mapping of c-akt: Relationship to v-akt and its implications
38. Isolation of transforming murine leukemia viruses from mice with a high incidence of spontaneous lymphoma
39. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: Amplification of AKT1 in a primary human gastric adenocarcinoma
40. The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB
41. Cellular survival: A play in three Akts
42. Regulation of survival signals from the insulin-like growth factor-I receptor
43. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
44. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-kinase/AKT in breast cancer cells
45. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways
46. Tyrosine 1062 of RET-MEN2A mediates activation of Akt (protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival
47. Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival
48. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway
49. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas
50. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas
51. Akt phosphorylates and negatively regulates apoptosis signal-regulating kinase 1
52. The p53 tumour suppressor gene
53. p53. Death star
54. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition
55. Key targets or the execution of radiation-induced tumor cell apoptosis: The role of p53 and caspases
56. Pharmacological rescue of mutant p53 conformation and function
57. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo
58. Induction of apoptosis in fibroblasts by c-Myc protein
59. Apoptosis inducers and anti-cancer agents: A high-throughput screen and identification of an apoptosis-inducing natural product with a novel mode of action
60. Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: Therapeutic implications
61. Novel synthetic organosulfur compounds induce apoptosis of human leukemic cells
62. p53 is required for radiation-induced apoptosis in mouse thymocytes
63. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors
64. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase
65. Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma
66. Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA)
67. Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate
68. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation
69. Selective induction of cyclin-dependent kinase inhibitors and their roles in cell cycle arrest caused by trichostatin A, an inhibitor of histone deacetylase
70. Second generation hybrid polar compounds are potent inducers of transformed cell differentiation
71. Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells
72. Phenylbutyrate-induced G1 arrest and apoptosis in myeloid leukemia cells: Structure-function analysis
73. WAF1 expression and gene-associated histone acetylation
74. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
75. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARα underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
76. Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL
77. Role of the histone deacetylase complex in acute promyelocytic leukaemia
78. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
79. Two critical hits for promyelocytic leukemia
80. Histone deacetylase inhibitors induce remission in a transgenic model of therapy resistant acute promyelocytic leukemia
81. Chromatin remodeling and leukemia: New therapeutic paradigms
82. Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells
83. The Hsp90 complex-a super-chaperone machine as a novel drug target
84. Signal-transduction cascades as targets for therapeutic intervention by natural products
85. Molecular chaperones: The busy life of Hsp90
86. Geldanamycin as a potential anti-cancer agent: Its molecular target and biochemical activity
87. Modulation of akt kinase activity by binding to hsp90
88. Negative regulation of cytochrome c-mediated oligomerization of apaf-1 and activation of procaspase-9 by heat shock protein 90
89. Disruption of hsp90 function results in degradation of the death domain kinase, receptor-interacting protein (RIP), and blockage of tumor necrosis factor-induced nuclear factor-kappaB activation
90. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin
91. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin
92. Pharmacology of competitive inhibitors of HMG-CoA reductase
93. HMG-CoA reductase inhibitors
94. Regulation of the mevalonate pathway
95. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: A potential therapeutic approach
96. Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia
97. Lovastatin induces apoptosis in malignant mesothelioma cells
98. Lovastatin-induced apoptosis of human medulloblastoma cell lines in vitro
99. Lovastatin induces growth inhibition and apoptosis in human malignant glioma cells
100. HMG-CoA reductase mediates the biological effects of retinoic acid on human neuroblastoma cells: Lovastatin specifically targets P-glycoprotein-expressing cells
101. HMG-CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture
102. Lovastatin augments sulindac-induced apoptosis in colon cancer cells and potentiates chemopreventive effects of sulindac
103. Lovastatin-induced apoptosis in prostate stromal cells
104. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells
105. Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells
106. Farnesyltransferase and geranylgeranyltransferase I inhibitors in cancer therapy: Important mechanistic and bench to bedside issues
107. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
108. Lovastatin induces a pronounced differentiation response in acute myeloid leukemias
109. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin